The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Should cure be the goal for multiple myeloma?
Sagar Lonial
• 9 Jun 2021
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses whether cure should be the goal for multiple myeloma, highlighting measurable residual disease (MRD)-negativity as an alternative goal, and the role of proteasome inhibitors and CELMoDs. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
